4th Annual Diabetes Forum Friday, May 7, 2010 | Executive Royal Inn – West Edmonton Chair: Lawrence Leiter, MD
Full detailed agenda will be available shortly!
This program meets the accreditation criteria of The College of Family Physicians of Canada and has been accredited by the Alberta Chapter for up to 5.5 Mainpro-M1 credits.
4th Annual Cardiac Update Saturday, May 8, 2010 | Executive Royal Inn – West Edmonton Chair: Anatoly Langer, MD
Full detailed agenda will be available shortly!
This program meets the accreditation criteria of The College of Family Physicians of Canada and has been accredited by the Alberta Chapter for up to 5.5 Mainpro-M1 credits.
07:30
Registration and Delegate Breakfast
08:20
Introduction
Lawrence Leiter, MD
Treatment Recommendations on
Diabetes Management
08:30
Timing and Tailoring: Tackling the challenges of type 2 diabetes in your daily practice: The need for early and aggressive management
Richard Lewanczuk, MD
08:50
Clinical Management of T2DM: Avoiding the complications of hypoglycemia
Philip Hardin, MD
09:10
Improving Diabetes Outcomes: How to organize your office
Maureen Clement, MD
09:30
The Role of ARB's in Diabetes and Kidney Disease
Philip Hardin, MD
09:50
Panel Discussion and Q & A with Audience Response System
All Faculty
10:20
Nutrition Break
Challenges in Achieving Metabolic Targets
10:40
Beyond Basal - When is once daily insulin insufficient?
Peter Senior, MD
11:00
New Canadian Dyslipidemia Guidelines: Take home messages
Lawrence Leiter, MD
11:20
Multiple Risk Factor Management in Patients with Diabetes
Jacques Romney, MD
11:40
Hypertension in Diabetes
Richard Lewanczuk, MD
12:00
Panel Discussion and Q & A with Audience Response System
All Faculty
12:30
Lunch
Managing Diabetes in Your Office
13:20
Case-Based Discussion
Case Presentations
Panel Discussion and Q & A with Audience Response System
Demonstrate improved working knowledge of current CDA guidelines with respect to achieving glycemic control, cholesterol lowering and vascular protection in patients with diabetes.
2.
Apply a clinically relevant (practical) approach to diagnosis and work-up of a patient with diabetes suspected of having coronary artery disease.
3.
Enhanced understanding of expected outcomes in patients with diabetes when targets for blood pressure, LDL and glycemic control are achieved.
Section 2
1.
Enhanced understanding of risks and benefits in lowering serum glucose based on pathophysiology and the results of recent clinical trials.
2.
Clearly differentiate between various therapeutic modalities currently available to lower blood glucose and be able to decide on the appropriate choices based on the patient's profile.
3.
Implement ability to assess clinical benefits associated with achievement of glycemic control.
Section 3
1.
Enhanced knowledge of the importance of dietary intervention as initial step in managing diabetes.
2.
Differentiate risk and benefit of therapy based on ethnic background of the patient.
3.
Enhanced knowledge of the risks and benefits of insulin therapy and be comfortable with transitioning their patients from oral to insulin therapy.
Program By participating in this program, participants will be able to:
1.
Understand and interpret results from recently published and presented clinical trials in cardiovascular and metabolic areas.
2.
Implement strategies for managing high-risk patients according to guidelines.
3.
Clearly differentiate between therapies for the treatment of high-risk patients with and without a prior diagnosis of cardiovascular disease.
4.
Differentiate the mechanism of action in the management of all agents available in the cardio-endocrine therapeutic continuum.
5.
Demonstrate improved ability to summarize the results of pre-clinical and clinical studies on therapies for acute coronary syndromes and stable CAD, as well as metabolic syndrome and diabetes.
07:30
Registration and Breakfast
08:20
Welcome
Anatoly Langer, MD
Management of Cardiovascular
Risk in Your Office
08:30
Life/Work Balance
Charl Els, MD
08:50
Protect What Counts
Gabor Gyenes, MD
09:10
Treatment Inertia: An educational program
Richard Lewanczuk, MD
09:30
Aspirin in Primary Prevention: Recommended by guidelines without support from data
Anatoly Langer, MD
09:50
Panel Discussion and Q & A with Audience Response System
All Faculty
10:20
Break
Innovation in Risk Stratification and Management of Dyslipidemia
10:40
GRIP: Getting guidelines rolled into practice
James Stone, MD
11:20
Practical Tips for Optimizing Success for Smoking Cessation
Milan Khara, MD
11:40
Closing the Care Gap in Cardiovascular Risk Reduction
Anatoly Langer, MD
12:00
Panel Discussion and Q & A with Audience Response System
All Faculty
12:30
Lunch
New Targets in Outpatient Practice
(Interactive session with Audience Response System)
13:20
Management of CVD in Your Office
· BP lowering: From stroke risk to
optimal therapy · Heart age and overall risk · Guidelines based management
Anatoly Langer, MD
Management of AF in Your Office
14:10
· Contemporary management of AF in your office · CHADS and recommendations
Enhanced understanding of risk stratification and evidence-based approach in managing patients with elevated blood pressure.
2.
Implement strategies for managing patients with complex cardiovascular disease and risk factors.
3.
3Demonstrate improved ability to understand the pathophysiology of RAAS system activation and clinical benefits of its inhibition at various levels.
Section 2
1.
Evaluate the use of serum biomarkers to identify at risk patients for unfavorable events.
2.
Evaluate the role of biomarkers for targeted vascular protection strategies based on recent evidence.
3.
Enhanced understanding of the changes and implications of the new Canadian guidelines for lipid lowering.
4.
Enhanced understanding of the role inflammation plays in the development and progression of cardiovascular disease.
Section 3
1.
Develop an evidence-based approach to using multiple drug classes in the management of high-risk cardiovascular patients and apply this approach to their clinical practice.
2.
Determine the appropriate evidence-based use of risk factor control and other proven therapies to provide vascular protection in high-risk patients.
3.
Understand and interpret results from recently published and presented clinical trials.
4.
Have increased ability to understand the recommendations and strategies for appropriate stroke prevention in patients with atrial fibrillation.
5.
Enhanced understanding of appropriate selection of anticoagulatant therapy in various subgroups of patients at risk for stroke.
Program By participating in this program, participants will be able to:
1.
Understand and interpret results from recently published and presented clinical trials.
2.
Implement strategies for managing patients with complex cardiovascular disease and risk factors.
3.
Determine the clinical significance of risk stratification and the applicability of the intervention according to the patient's risk.
4.
Clearly differentiate between therapies, medical and pharmaceutical based, for the treatment of patients with and without prior diagnosis of cardiovascular disease.
5.
Have increased ability to differentiate the mechanism of action in the management of disorders such as hypertension, dyslipidemia, diabetes, heart failure and arrhythmia through review of available agents.
6.
Have increased ability to summarize the results of pre-clinical and clinical studies in therapeutic areas such as hypertension, dyslipidemia, diabetes, heart failure and arrhythmia.
